GlassScriptPhysician profile
Wenona Dotson
NPI 1154637288
$2,513.23
in general payments reported to CMS, 2019-2025
24 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $868 · 2023: $454 · 2024: $246 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $827.47 | 2021-2025 | |
| Novo Nordisk INC | $408.78 | 2021-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $337.35 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $101.88 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $95.54 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.55 | 2021-2023 | |
| Lilly USA, LLC | $83.36 | 2021-2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $80.47 | 2021-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.76 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $67.93 | 2022 | |
| Axsome Therapeutics, INC. | $53.42 | 2025 | Auvelity |
| Amgen INC. | $52.74 | 2022 | |
| Abbott Laboratories | $37.56 | 2021-2023 | Proclaim |
| Glaxosmithkline, LLC. | $29.41 | 2023 | Trelegy Ellipta |
| Nevro Corp. | $21.93 | 2023 | Senza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $19.52 | 2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.46 | 2024 | Xifaxan, Trulance |
| Organon LLC | $19.29 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $18.77 | 2025 | |
| Phadia US INC. | $16.22 | 2023 | Immunocap |
| Dexcom, INC. | $14.88 | 2023 | Dexcom G6 Transmitter |
| Cequr Corporation | $14.10 | 2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $13.84 | 2025 | Lagevrio |
| Exact Sciences Corporation | $13.00 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wenona Dotson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.